Skip to content

Clinical predictors of recurrence and malignization of Oral Leukoplakia and Proliferative Verrucous Leukoplakia: a randomized clinical trial

Clinicopathological and digital predictors of recurrence and malignancy of Oral Leukoplakia and Proliferative Verrucous Leukoplakia: a clinical study associated with artificial inteligence

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-4v36p2h
Enrollment
Unknown
Registered
2024-06-01
Start date
2023-04-18
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukoplakia

Interventions

This is a double-blind, randomized controlled clinical trial. Patients will be stratified by epidemiological characteristics and clinical features of the lesion. Block randomizations will be generated
(2) PVL treatment (complete removal of site-specific lesion) will be performed by applying a high-power diode laser, in surgical mode, (DMC U.S.A Plantation, FL, USA,), 940nm, 4 watts, pulsed mode, 10
(3) Treatment of OL will be performed by conventional surgical removal (n=30)
(4) Treatment of PVL will be performed by conventional site-specific surgical removal (n=30). Patients recruited and enrolled in the clinical study will be followed up on a quarterly basis for 24 mont

Sponsors

Universidade Estadual de Campinas
Lead Sponsor
Universidade Estadual de Campinas
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: We will select 60 patients diagnosed with oral leukoplakia (OL) and 60 patients with proliferative verrucous leukoplakia (PVL) through biopsy and histological analysis. Only patients presenting with OL and PVL located in any region in the oral cavity will be selected. It is estimated that the participants will be mostly male smokers over 50 years of age for the diagnosis of OL and non-smoking women over 60 years of age for the diagnosis of PVL.

Exclusion criteria

Exclusion criteria: We will excluded patients with a history of previous oral carcinomas, chemotherapy, or radiation therapy in the head and neck region.

Design outcomes

Secondary

MeasureTime frame
We expect to find better healing and post-operative pain results in the laser arm when compared to the scalpel in the two-year follow-up period, using the Vancouver healing scale and the visual analog scale, respectively.

Primary

MeasureTime frame
It is hoped to find a reduction in the number of recurrences and malignant transformations in the laser arm compared to the scalpel arm over the two-year follow-up period, based on a variation of at least 5% in the pre- and post-intervention measurements.

Countries

Brazil

Contacts

Public ContactCaique Pedroso

Universidade Estadual de Campinas

caiquemar@gmail.com+55(42) 99115-4613

Outcome results

None listed

Source: REBEC (via WHO ICTRP)